Cargando…
Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control;...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966497/ https://www.ncbi.nlm.nih.gov/pubmed/27524885 http://dx.doi.org/10.2147/PPA.S106821 |
_version_ | 1782445390878998528 |
---|---|
author | Polonsky, William H Henry, Robert R |
author_facet | Polonsky, William H Henry, Robert R |
author_sort | Polonsky, William H |
collection | PubMed |
description | At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes. Poor medication adherence is linked to key nonpatient factors (eg, lack of integrated care in many health care systems and clinical inertia among health care professionals), patient demographic factors (eg, young age, low education level, and low income level), critical patient beliefs about their medications (eg, perceived treatment inefficacy), and perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia). Specific barriers to medication adherence in T2D, especially those that are potentially modifiable, need to be more clearly identified; strategies that target poor adherence should focus on reducing medication burden and addressing negative medication beliefs of patients. Solutions to these problems would require behavioral innovations as well as new methods and modes of drug delivery. |
format | Online Article Text |
id | pubmed-4966497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49664972016-08-12 Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors Polonsky, William H Henry, Robert R Patient Prefer Adherence Review At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes. Poor medication adherence is linked to key nonpatient factors (eg, lack of integrated care in many health care systems and clinical inertia among health care professionals), patient demographic factors (eg, young age, low education level, and low income level), critical patient beliefs about their medications (eg, perceived treatment inefficacy), and perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia). Specific barriers to medication adherence in T2D, especially those that are potentially modifiable, need to be more clearly identified; strategies that target poor adherence should focus on reducing medication burden and addressing negative medication beliefs of patients. Solutions to these problems would require behavioral innovations as well as new methods and modes of drug delivery. Dove Medical Press 2016-07-22 /pmc/articles/PMC4966497/ /pubmed/27524885 http://dx.doi.org/10.2147/PPA.S106821 Text en © 2016 Polonsky and Henry. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Polonsky, William H Henry, Robert R Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
title | Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
title_full | Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
title_fullStr | Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
title_full_unstemmed | Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
title_short | Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
title_sort | poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966497/ https://www.ncbi.nlm.nih.gov/pubmed/27524885 http://dx.doi.org/10.2147/PPA.S106821 |
work_keys_str_mv | AT polonskywilliamh poormedicationadherenceintype2diabetesrecognizingthescopeoftheproblemanditskeycontributors AT henryrobertr poormedicationadherenceintype2diabetesrecognizingthescopeoftheproblemanditskeycontributors |